Tanım

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 milyon itibaren 2022 ile 2028, garnering a CAGR of 16.1% tahmin dönemi boyunca.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2018-2021 ve tahmin 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, başvuru, biomarker type, teknoloji, ve bölge. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), diğerleri (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 ve tahmin dönemi boyunca payını koruması bekleniyor. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, diğerleri. İçinde 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), diğerleri. Bunların arasında, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. In terms of geography, the global liquid biopsy market has been segmented into Asia Pacific, Avrupa, Kuzey Amerika, Dünyanın Geri Kalanı (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Ltd., Becton Dickinson and Company, Berry Genomics Co. Ltd., BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Therapy: oncology, noninvasive prenatal testing (NIPT), diğerleri (e.g. organ transplant)
Başvuru: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, diğerleri
Teknoloji: next-generation sequencing (NGS), polymerase chain reaction (PCR), diğerleri
Bölge: Asya Pasifik, Avrupa, Kuzey Amerika, Dünyanın Geri Kalanı (RoW)
Dikkate alınan yıllar: bu rapor dönemi kapsamaktadır 2018 ile 2028

Paydaşlar için Temel Faydalar

– Get a comprehensive picture of the global liquid biopsy market
– Büyüme sektörlerini ve yatırım eğilimlerini belirleyin

İçindekiler

Parça 1. giriiş
– Çalışmanın kapsamı
– Çalışma periyodu
– Coğrafik kapsam
– Araştırma metodolojisi
Parça 2. Liquid biopsy market overview
Parça 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– Diğerleri (e.g. organ transplant)
Parça 4. Market breakdown by application
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
Parça 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– Diğerleri
Parça 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– Diğerleri
Parça 7. Market breakdown by region
– Asya Pasifik
– Avrupa
– Kuzey Amerika
– Dünyanın Geri Kalanı (RoW)
Parça 8. Anahtar şirketler
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., Ltd..
– Becton, Dickinson and Company
– Berry Genomics Co., Ltd..
– BGI Group
– Biocartis Group
– Biocept, A.Ş..
– Biodesix, A.Ş..
– Biolidics Limited
– Bio-Rad Laboratories, A.Ş..
– Bio-Techne Corp.
– CareDx, A.Ş..
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, A.Ş..
– Koninklijke Philips N.V..
– Merck KGaA
– Myriad Genetics, A.Ş..
– NeoGenomics Laboratories, A.Ş..
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, A.Ş..
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
StratejiHelix Hakkında
Sorumluluk reddi beyanı